Abstract
Tamoxifen treatment revolutionized the management of estrogen receptor (ER) positive breast cancers, however drug resistance compromises its clinical efficacy. We here investigate effect of VEGFR signal pathway inhibitor apatinib on tamoxifen resistant breast cancer cell line and its possible mechanism.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
